These effects have also been observed in NSCLC cell lines under gefitinib/erlotinib exposure [31] and in mouse- and human-derived SCLC cells treated with the cancer drugs etoposide, carboplatin, cisplatinum and/or the SHH-antagonist NVP-LDE225 [36]. The gene discussed is SHH; the disease is non-small cell lung carcinoma.